Your Article Summary
See Latest ArticlesSitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations
Antimicrobial Agents and Chemotherapy, 06/25/09
Murakami K et al. - Sitafloxacin showed MICs of less than or equal to 0.5 µg/ml against 105 isolates of Helicobacter pylori, including 44 isolates with mutations in the gyrA gene. The highest MICs for garenoxacin and levofloxacin were 8 and 64 times, respectively, higher than the highest MICs observed for sitafloxacin.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease
Journal of Cancer Research & Clinical Oncology, 12/04/09
Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms
BMC Gastroenterology, 12/04/09
Variants in the UGT1A1 Gene and the Risk of Pediatric Nonalcoholic Fatty Liver Disease
Pediatrics, 12/02/09
Today in GI Infectious Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
A systematic review of serologic tests in the diagnosis of necrotizing enterocolitis
Journal of Pediatric Surgery, 12/04/09
The epidemiology of hospitalization with diarrhea in rural Kenya: the utility of existing health facility data in developing countries
International Journal of Infectious Diseases, 12/04/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Annals of Oncology, 12/04/09
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
Annals of Oncology, 12/04/09